Computational drug screening has shown that chemotherapy drug pralatrexate could potentially be repurposed to treat COVID-19.
List view / Grid view
Filter the results
In this article Andrew Nyborg from Horizon Therapeutics discusses why researchers are taking a second look at gout and how they are modelling the condition, which is unique to humans.
Study shows that haematoxylin can selectively kill cancers with a mutated form of the calreticulin gene (CALR), common in a group of bone marrow cancers called myeloproliferative neoplasms (MPNs).
A team has found that their drug Molnupiravir (MK-4482/EIDD-2801) acts as an antiviral against SARS-CoV-2 in pre-clinical studies.
A group of researchers has found a drug candidate named TRV027 that can increase the cardiac contractility of neonatal mice.
Researchers have found a compound that can prevent up-regulation of CD14, a key inflammatory protein, in cells.
Researchers have identified hepatitis C drugs that can inhibit the SARS-CoV-2 main protease, which enables the coronavirus to reproduce.
The tool uses interactive molecular dynamics simulations in virtual reality (iMD-VR) to allow researchers to step inside SARS-CoV-2 enzymes and visualise molecules binding to them.
Researchers have found that aprotinin, an approved drug for influenza in Russia, combats SARS-CoV-2 in cells.
The high level of outsourcing of hit-to-lead processes will make it the fastest-growing segment of the drug discovery service market, a new report says.
High-throughput screening is a common method of identifying lead compounds for drug development. The most common targets are enzymes – catalytic proteins that perform chemical reactions in the cell. In this article, Matthew Lloyd discusses the opportunities and challenges associated with this approach.
Researchers have found a lead compound which they say inhibits SARS-CoV-2 viral replication and demonstrates good pharmacokinetic activity in vivo.
A new method has been developed by researchers to create synthetic molecules which replicate natural structures and have potential medicinal uses.
Open innovation – a collaboration between academia and the pharmaceutical industry to further leverage drug discovery expertise and assets
Increasing numbers of companies in the pharma industry are consolidating their services and outsourcing to CROs to reduce business costs. AstraZeneca’s Marian Preston, David Murray and Mark Wigglesworth discuss how this can not only drive innovation but also prove successful in identifying lead compounds, as evidenced through recent collaborations.